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Epidemiology of systemic lupus
erythematosus in the United Kingdom:
comment on the article by Somers et al
To the Editors:
We read with interest the article by Somers et al in
Arthritis Care & Research reporting on the incidence of
systemic lupus erythematosus (SLE) in the UK (1). This
study suggests a markedly higher incidence rate for SLE
than we found using the same database (2) and we imagine
your readers will be interested in understanding how these
differences arose.
Various methodologic issues need to be considered
when estimating the incidence of a chronic relapsing–
remitting disease such as SLE using a clinical database (3).
One such issue is the duration for which SLE patients can
be in remission. To enable the distinction between inci-
dent (new) and prevalent (pre-existing) cases, the investi-
gator needs to be confident that the first record encoun-
tered in the database is actually the first occurrence of the
disease for that patient. To account for this, a minimum
period of registration before diagnosis needs to be defined.
Lewis et al (4) described how this minimum period of time
will differ between acute, chronic, and neoplastic out-
comes, and concluded that patients’ “early portion of fol-
low-up” should be excluded, with the duration of this
followup portion varying by disease and being longest for
chronic recurrent diseases. We chose to require 3 years’
prior data without any record of SLE before we accepted
the SLE patients identified as likely incident cases, rather
than patients who were having an SLE flare or relapse. For
the entire study population, therefore, the first 3 years of
data did not contribute to the denominator in calculating
the incidence rates. The choice of 3 years was based on the
reported mean  SD duration of remission for patients
with SLE, which varies between studies but is generally
reported to be 2.3  1.1 years (5). Somers et al required 1
years’ worth of data before first diagnosis (1). If 1 year is
indeed enough, then the resulting incidence rates should
be the same as a 3-year period, since the amount of person-
time discarded from the study is accounted for in the
calculation of the denominator. However, if 1 year is not
enough, then this will have led to the inclusion of preva-
lent cases in the study by Somers et al, resulting in over-
estimated incidence rates.
From our understanding of the article, Somers and col-
leagues included patients based on the identification of
relevant medical codes (1), which presents an additional
problem. In our study we required supporting evidence for
a diagnosis such as relevant drug treatment, a diagnosis
made in a hospital (we assumed this would have been by
a rheumatologist), and/or meeting 4 American College of
Rheumatology (ACR) criteria (2,6). In contrast to conduct-
ing automated searches only, we manually reviewed
4,500 potential cases initially identified. For the largest
part of the database, free text comments were available
with diagnoses, which informed our decision as to
whether the potential case was incident or not and
whether the patient was an SLE patient or not. For in-
stance, free text recorded together with an SLE diagnosis
could state “excluded.” At this stage, we excluded many
patients we believed to have disseminated or cutaneous
forms rather than systemic-type lupus, prevalent rather
than incident, and rheumatoid arthritis rather than SLE.
We believe that as a result of our requirement for sup-
porting evidence of a diagnostic code combined with our
manual review of the full patients’ records, we excluded
more cases than we would have if we had carried out the
research in the same way as Somers et al. We believe the
study by Somers and colleagues was at a higher risk of
including prevalent SLE cases and those that were not
actually SLE patients. This will have led to overestimated
rates.
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We thank de Vries et al for their interest in our study and
reiterating for the readers that their prior analysis of General
Practice Research Database (GPRD) data yielded a lower in-
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cidence estimate of SLE compared with our findings (1). An
additional cause of difference to those they mentioned is that
we standardized for age and they did not. The difference in
estimates underscores the importance of a thorough under-
standing of the complexities of both the GPRD and SLE when
analyzing and interpreting results based on this data set.
An important distinction between these 2 studies is that,
as detailed in our article, our group conducted an analysis
in accordance with the published methodology of Lewis et
al (2) in order to determine the appropriate analysis time
window to differentiate between prevalent and incident
cases. Based on our empirical findings, we determined that
patients who registered with a general practitioner (GP)
after the GP contributed data to the GPRD needed a mini-
mum of 1 year of followup in order to be eligible for the
analysis. In contrast, Nightingale et al (1) made a decision
to exclude the first 3 years of followup for all patients.
They justified their choice of a 3-year window because in
their understanding the “average duration of remission for
SLE patients” is mean  SD 2.3  1.1 years, based on
findings published by Barr et al on SLE disease activity
patterns from the Hopkins Lupus Cohort (3). However, the
study by Barr et al actually showed that only a minority of
SLE person-years were characterized by a “long quiescent”
pattern of disease activity (16%), with remaining person-
time classified as “chronic active” or “relapsing–remit-
ting,” which by definition involves disease activity during
a given year. The average remission duration only applies
to the “long quiescent” fraction of person-time. Moreover,
it is unclear how even an accurate summary measure for
the average length of remission would translate into a
meaningful time window for the differentiation of preva-
lent and incident cases, since the standard of care for SLE
requires medical followup during apparent quiescent pe-
riods to enable detection of subclinical disease (e.g., renal
involvement). Use of a long exclusion period can further
introduce bias if patients with followup of 3 years differ
systematically from those with shorter followup.
As we discussed in our article, a limitation of the GPRD
is that data related to ACR criteria for SLE, including
autoantibody profiles, are not uniformly available, i.e., the
lack of such data should not be confused with a negative
result. Also, certain therapeutics (e.g., cyclophosphamide)
that are prescribed by hospital consultants rather than GPs
are not recorded in the GPRD. Nevertheless, Nightingale et
al included ACR criteria or prescriptions for medications
such as cyclophosphamide as part of their case definition.
However, the application of ACR criteria (assuming it was
a valid approach in this setting) versus physician diagno-
sis could indeed account for differences in incidence esti-
mates, since the classification criteria have limited sensi-
tivity when applied to external populations (85%), as
opposed to the initial test population (4,5). For this reason,
efforts are underway in the SLE community to develop a
set of criteria that performs better.
We have chosen to use standard definitions that can apply
to the whole data set. We believe that there is potential bias
when criteria, whether ACR or free text, can only be applied
to a proportion, and often a small proportion, of the database.
A final point worth recapitulating from our article is that as
external validation of our methodology, we compared our
region-specific incidence estimates with those from 2 active
surveillance studies based in the same geographic regions,
yielding remarkably similar findings (and within the confi-
dence intervals) to those independent studies. We estimated
an age-adjusted incidence (per 100,000) of 3.56 for the West
Midlands (similar to 3.8 published for Birmingham [6]) and
4.37 for Trent (similar to 4.0 published for Nottingham [7]).
In summary, we believe that the consistent methodology
we used is likely to have resulted in more accurate esti-
mates than those proposed by Nightingale et al, as indi-
cated by the external validity.
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